Curaleaf Takes Action Against Aurora's ATM Program Amid Acquisition Efforts
In the evolving narrative of the cannabis industry, Curaleaf Holdings, Inc., a prominent player in the sector, has officially lodged an application with the Alberta Securities Commission (ASC) demanding the suspension of Aurora Cannabis Inc. (Aurora) from executing its at-the-market (ATM) share issuance program. This move comes amid Curaleaf's attempt to acquire all outstanding shares of Aurora, highlighting the potential adverse effects this program could have on shareholder value during the acquisition process.
Curaleaf argues that Aurora's recent share sales through the ATM program not only dilute existing shareholder ownership but are also a strategic maneuver aimed at obstructing the acceptance of Curaleaf's favorable acquisition offer, which has sparked a debate about the ethicality of Aurora's practices. The company claims that since the inception of the ATM program in February 2026, approximately 2.81 million shares were issued, resulting in a dilution of about 10.8% for shareholders. This dilution has inflated the cost of Curaleaf's acquisition bid by over $11 million, raising important questions about corporate governance and shareholder rights.
Boris Jordan, the CEO of Curaleaf, expressed concerns that the issuance of these shares undermines shareholders' ability to make informed decisions regarding the Curaleaf offer. "If the management of Aurora believes that their shares are undervalued at $4.00 while they boast of an industry-leading balance sheet and sufficient cash reserves, one must question why they would continue to dilute their shareholders' ownership," he stated. Jordan’s comments underline a growing frustration among investors who feel sidelined by management tactics designed to maintain control.
The Application submitted by Curaleaf detailed several instances of how Aurora's continuous share issuances obstruct other shareholder interests. Primarily, these actions complicate the acceptance thresholds required for Curaleaf’s offer, thereby further diluting the stock and eroding potential opportunities for shareholders to take part in a transaction they might find beneficial.
Aurora's justification for the ATM program was initially framed as a strategic move towards growth, intended for ‘strategic and accretive purposes only’. Nevertheless, Curaleaf contends that given Aurora's current financial standing—they recently referenced being debt-free with approximately C$149 million in cash—this program appears misaligned with their admitted financial health. Furthermore, Curaleaf highlights that ongoing share issuances despite Aurora's awareness of Curaleaf’s acquisition interest since mid-2026 reflect an disturbing disregard for shareholder welfare.
In its application, Curaleaf calls for immediate action from the ASC to halt further issuances of shares under this program while the acquisition offer remains open, arguing that this course of action would help maintain the integrity of Alberta's capital markets and ensure equitable treatment of all shareholders involved in this contentious situation.
Curaleaf aims to reassure Aurora's shareholders that they are committed to providing a meaningful opportunity for them, fostering the chance for significant returns, and enabling them to partake in the continued expansion of the cannabis market through a potential merger.
Potential and existing shareholders are prudently advised to thoroughly review all related documentation surrounding the acquisition offer before making any decisions, as the nuances in this context significantly impact their investment choices. Curaleaf has made these documents available across multiple platforms including their official website, SEDAR+, and EDGAR, in hopes of fostering transparency throughout this complex process. As the scenario develops, both stakeholders and industry analysts will be closely monitoring how this situation evolves, particularly in regards to shareholder rights and corporate governance practices in the ever-changing landscape of cannabis legislation and market dynamics.
Curaleaf argues that Aurora's recent share sales through the ATM program not only dilute existing shareholder ownership but are also a strategic maneuver aimed at obstructing the acceptance of Curaleaf's favorable acquisition offer, which has sparked a debate about the ethicality of Aurora's practices. The company claims that since the inception of the ATM program in February 2026, approximately 2.81 million shares were issued, resulting in a dilution of about 10.8% for shareholders. This dilution has inflated the cost of Curaleaf's acquisition bid by over $11 million, raising important questions about corporate governance and shareholder rights.
Boris Jordan, the CEO of Curaleaf, expressed concerns that the issuance of these shares undermines shareholders' ability to make informed decisions regarding the Curaleaf offer. "If the management of Aurora believes that their shares are undervalued at $4.00 while they boast of an industry-leading balance sheet and sufficient cash reserves, one must question why they would continue to dilute their shareholders' ownership," he stated. Jordan’s comments underline a growing frustration among investors who feel sidelined by management tactics designed to maintain control.
The Application submitted by Curaleaf detailed several instances of how Aurora's continuous share issuances obstruct other shareholder interests. Primarily, these actions complicate the acceptance thresholds required for Curaleaf’s offer, thereby further diluting the stock and eroding potential opportunities for shareholders to take part in a transaction they might find beneficial.
Aurora's justification for the ATM program was initially framed as a strategic move towards growth, intended for ‘strategic and accretive purposes only’. Nevertheless, Curaleaf contends that given Aurora's current financial standing—they recently referenced being debt-free with approximately C$149 million in cash—this program appears misaligned with their admitted financial health. Furthermore, Curaleaf highlights that ongoing share issuances despite Aurora's awareness of Curaleaf’s acquisition interest since mid-2026 reflect an disturbing disregard for shareholder welfare.
In its application, Curaleaf calls for immediate action from the ASC to halt further issuances of shares under this program while the acquisition offer remains open, arguing that this course of action would help maintain the integrity of Alberta's capital markets and ensure equitable treatment of all shareholders involved in this contentious situation.
Curaleaf aims to reassure Aurora's shareholders that they are committed to providing a meaningful opportunity for them, fostering the chance for significant returns, and enabling them to partake in the continued expansion of the cannabis market through a potential merger.
Potential and existing shareholders are prudently advised to thoroughly review all related documentation surrounding the acquisition offer before making any decisions, as the nuances in this context significantly impact their investment choices. Curaleaf has made these documents available across multiple platforms including their official website, SEDAR+, and EDGAR, in hopes of fostering transparency throughout this complex process. As the scenario develops, both stakeholders and industry analysts will be closely monitoring how this situation evolves, particularly in regards to shareholder rights and corporate governance practices in the ever-changing landscape of cannabis legislation and market dynamics.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.